samedan logo
 
 
 
spacer
home > pmps > summer 2008 > rfid to the rescue
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

RFID to the Rescue

During the development process of new therapeutic approaches, multi-phase clinical research studies (clinical trials) are the last hurdle to overcome. Hence clinical trials represent one of the crucial steps in the development of a new drug. In view of increasing competition, rising cost pressures and, above all, the need to bring new products to market as quickly as possible, the current process of clinical trial supply management harbours inefficiencies, which can be eliminated by innovative RFID-based technologies.

‘TIME TO MARKET’ IS CRUCIAL

The total costs of developing a new drug or treatment up to the point of approval can amount to as much as US$ 1 billion. Typically, a new drug will have been subjected to around 10 years of stringent preclinical testing before entering the first of a total of three clinical trial phases. Nonetheless, according to information published by the FDA in 2004, a new drug has merely an eight per cent chance of achieving final approval and thus being brought to market. One of the reasons for this is the fact that results obtained in animal tests can be applied to humans only to a limited extent: around 90 per cent of substances found to be safe with lab animals fail the test of subsequent clinical trials on humans.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Guido Moosmann is Business Development Director RFID at Schreiner MediPharm, one of the major divisions of Schreiner Group based in Oberschleissheim near Munich, Germany. Guido has extensive academic and industry experience in the field of RFID technologies. He is the author and co-author of various studies and books on source tagging and RFID standards.
spacer
Guido Moosmann
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

SGD Pharma introduces Ensiemo, the new complete child-resistant packaging solution for CBD oils

SGD Pharma today announces the launch of its new full packaging solution dedicated to the cannabidiol (CBD) oil market. Combining the company’s extensive pharmaceutical packaging expertise with the need for compliant, safe packaging for CBD oils, SGD Pharma has developed Ensiemo – a glass dropper and bottle offering that meets international regulatory standards.
More info >>

White Papers

Backward Thinking

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement